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Abstract
Objectives To summarise evidence on the associations of maternal
anaemia and prenatal iron use with maternal haematological and adverse
pregnancy outcomes; and to evaluate potential exposure-response
relations of dose of iron, duration of use, and haemoglobin concentration
in prenatal period with pregnancy outcomes.
Design Systematic review and meta-analysis
Data sources Searches of PubMed and Embase for studies published
up to May 2012 and references of review articles.
Study selection criteria Randomised trials of prenatal iron use and
prospective cohort studies of prenatal anaemia; cross sectional and
case-control studies were excluded.
Results 48 randomised trials (17 793 women) and 44 cohort studies (1
851 682 women) were included. Iron use increased maternal mean
haemoglobin concentration by 4.59 (95% confidence interval 3.72 to
5.46) g/L compared with controls and significantly reduced the risk of
anaemia (relative risk 0.50, 0.42 to 0.59), iron deficiency (0.59, 0.46 to
0.79), iron deficiency anaemia (0.40, 0.26 to 0.60), and low birth weight
(0.81, 0.71 to 0.93). The effect of iron on preterm birth was not significant
(relative risk 0.84, 0.68 to 1.03). Analysis of cohort studies showed a
significantly higher risk of low birth weight (adjusted odds ratio 1.29, 1.09
to 1.53) and preterm birth (1.21, 1.13 to 1.30) with anaemia in the first
or second trimester. Exposure-response analysis indicated that for every
10 mg increase in iron dose/day, up to 66 mg/day, the relative risk of
maternal anaemia was 0.88 (0.84 to 0.92) (P for linear trend<0.001).
Birth weight increased by 15.1 (6.0 to 24.2) g (P for linear trend=0.005)
and risk of low birth weight decreased by 3% (relative risk 0.97, 0.95 to
0.98) for every 10 mg increase in dose/day (P for linear trend<0.001).
Duration of use was not significantly associated with the outcomes after
adjustment for dose. Furthermore, for each 1 g/L increase in mean
haemoglobin, birth weight increased by 14.0 (6.8 to 21.8) g (P for linear
trend=0.002); however, mean haemoglobin was not associated with the
risk of low birth weight and preterm birth. No evidence of a significant
effect on duration of gestation, small for gestational age births, and birth
length was noted.
Conclusions Daily prenatal use of iron substantially improved birth
weight in a linear dose-response fashion, probably leading to a reduction
in risk of low birth weight. An improvement in prenatal mean haemoglobin
concentration linearly increased birth weight.
Introduction
Iron deficiency is the most widespread nutritional deficiency in
the world.1 2 It is the most common cause of anaemia during
pregnancy. Other causes include parasitic diseases such as
malaria, hookworm infections, and schistosomiasis;
micronutrient deficiencies including folic acid, vitamin A, and
vitamin B12; and genetically inherited haemoglobinopathies
such as thalassaemia.3According to the Nutrition Impact Model
Study’s 2011 estimates, the worldwide prevalence of anaemia
in pregnant women was 38% (95% confidence interval 33% to
43%), translating into 32 (28 to 36) million pregnant women
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globally.4 Because of the persistently high burden of disease,
the World Health Organization has long recommended the
prenatal use of iron supplements in low and middle income
countries, and this is also recommended in many high income
countries.1 5 6
In 2011 more than 50% of anaemia in pregnant women was due
to iron deficiency in regions where fewer other causes were
present.4 Multiple observational studies on prenatal anaemia
and only a few on iron deficiency anaemia are available.7 8 One
of the main reasons is the use of haemoglobin concentration as
a proxy for iron deficiency anaemia due to its low cost and
relative ease of determination. Reviews of observational studies
show an association between prenatal anaemia and risk of
preterm birth, but evidence for other outcomes is inconsistent.9-11
Clinical trials of prenatal iron supplementation have shown
improvement in haemoglobin concentration, but evidence of an
effect on birth outcomes has been found to be inconclusive.12 13
The Cochrane review on prenatal iron supplementation found
no evidence of a reduction in risk of low birth weight and
preterm birth,12 whereas Imdad et al showed a reduction in risk
of low birth weight only.14 Because of the conflicting findings
from reviews of observational studies and randomised trials,
we have done a comprehensive systematic review evaluating
all evidence by collating data from randomised trials and
prospective cohort studies in one report. Furthermore, to the
best of our knowledge, no systematic evaluation has been done
of exposure-response relations of iron dose and haemoglobin
concentration in the prenatal period with adverse birth outcomes,
identification of which would prove critical to the efforts to
reduce this burden.
We did a meta-analysis of randomised trials of the overall effect
of use of iron, with or without folic acid, on maternal
haematological status, morbidity, and birth outcomes and
evaluated the existence and shape, whether linear or non-linear,
of the iron dose-response relation with risk of maternal anaemia,
birth weight, and risk of low birth weight and preterm birth.
Because a greater proportion of women in low and middle
income countries seek antenatal care late in pregnancy, we also
evaluated the relation of these outcomes with the duration of
iron use. As cohort studies often have larger sample sizes and
are more likely to have measured baseline haemoglobin, we
then summarized evidence from prospective cohort studies by
doing a meta-analysis examining the association of prenatal
anaemia with birth outcomes. Finally, we assessed
exposure-response relations of haemoglobin concentration with
birth weight and risk of low birth weight and preterm birth by
using data from trials with haemoglobinmeasurement and cohort
studies, and we compared the magnitude of these associations.
Methods
We followed the Cochrane Collaboration’s method for this
review.15We did comprehensive, systematic literature searches
of PubMed (from 1966 to 31 May 2012), and Embase (from
1974 to 31May 2012).We developed separate search strategies
consisting of a combination of free text words (tw), words in
titles/abstracts (tiab), and medical subject headings (mesh) for
exposure, participants, and study design; we then combined
these by using “AND” (see box). We placed no language or
publication restrictions.We adapted the PubMed search strategy
for Embase. We screened reference lists of identified studies
and published reviews for additional studies.
Study selection
Two reviewers (BAH and IO) independently screened titles and
abstracts. They then critically reviewed full texts of selected
studies to assess eligibility. Any discrepancy between the
reviewers was resolved through discussion.
We included randomised trials in pregnant women of daily oral
iron or iron and folic acid use compared with placebo, no iron,
or no iron and folic acid. We included trials of both
supplementation and fortification.We excluded trials of multiple
vitamins andminerals, except those that examined the additional
effect of iron or iron with folic acid in which all treatment groups
received similar vitamins and minerals (except for iron or iron
and folic acid). We included trials examining maternal
haematological, morbidity, and birth outcomes. Maternal
haematological outcomes included mean haemoglobin
concentration (g/L), anaemia (defined as haemoglobin <110
g/L), iron deficiency (defined as serum ferritin <12 µg/L), and
iron deficiency anaemia (defined as haemoglobin <110 g/L and
serum ferritin <12 µg/L) in the second or third trimester or at
delivery and in the postpartum period. Birth outcomes included
mean duration of gestation (weeks), preterm birth (defined as
birth of a neonate <37 weeks of gestation), mean birth weight
(g), low birth weight (defined as birth weight <2500 g), mean
birth length (cm), small for gestational age birth (defined as
birth weight below the 10th centile of the gestational age and
sex), stillbirth (defined as death of a fetus after 28 weeks of
gestation), perinatal mortality (defined as deaths including
stillbirths and neonatal deaths before 7 days of life), and neonatal
mortality (defined as death of a neonate in the first month of
life). Other maternal outcomes included gestational diabetes
mellitus, infection during pregnancy and postpartum, maternal
malaria and parasitaemia, and placental malaria. We placed no
limits on gestational age at the time of starting iron or duration
of iron use.We included both individual and cluster randomised
trials.
For analysis of observational studies, we included prospective
cohort studies that allowed examination of the association of
baseline anaemia with the above specified birth outcomes. We
included studies defining anaemia as haemoglobin <100 g/L to
haemoglobin <115 g/L. When haemoglobin was not reported
but haematocrit was available, we estimated haemoglobin
concentrations (g/L) by dividing haematocrit by 3 and then
multiplying by 10.We excluded cross sectional and case-control
studies, as these do not allow assessment of the temporal
association between exposure and an outcome.We also excluded
trials with a quasi-randomised design owing to the high risk of
bias and studies in HIV infected women or those with
haemoglobinopathies. We excluded trials evaluating different
doses of iron, unless they presented comparison groups that met
our eligibility criteria.
Data extraction and synthesis
Two reviewers (BAH and IO) independently extracted data by
using a pilot tested data extraction form. We collected
information from each study on study design, setting,
participants, exposure, time of assessment of exposure,
outcomes, confounders, and measures of association. Exposure
details for trials included treatment, dose, gestational age at
start, and duration and frequency of iron use; for cohort studies,
we recorded definition of anaemia and time of assessment. We
extracted raw data and effect estimates (relative risks or odds
ratios) with 95% confidence intervals. We extracted odds ratios
from cohort studies; when available in the original publication,
we also extracted odds ratios adjusted for the potential
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Search strategy
#1 “iron compounds” [mesh] OR “iron” [mesh] OR “hematinics” [mesh] OR “iron” [tiab] OR “ferrous” [tiab] OR “ferric” [tiab] OR “hematinics”
[tiab] OR “hematinic” [tiab] OR “haematinic” [tiab] OR “haematinics” [tiab] OR “anemia” [mesh] OR “anaemia” [tiab] OR “anemia” [tiab]
OR “haemoglobin” [tiab] OR “hemoglobin” [tiab] OR “ferritin” [tiab]) OR “haematocrit” [tiab] OR “ hematocrit”[tiab]
#2 “Pregnant Women”[mesh] OR “Pregnancy”[mesh] OR pregnan* [tiab] OR “gravid” [tiab] OR “obstetric” [tiab] OR “antenatal” [tiab] OR
“antepartum” [tiab] OR gestation* [tiab]
#3 “Cohort Studies” [mesh] OR “Longitudinal Studies” [mesh] OR “follow up studies” [mesh] OR “prospective studies” [mesh] OR “Case
Control Studies” [mesh] OR “Retrospective Studies” [mesh] OR “controlled clinical trial” [pt] OR “randomized controlled trial” [pt] OR
“clinical trial” [pt] OR cohort* [tiab] OR “longitudinal” [tiab] OR “prospective” [tiab] OR “retrospective” [tiab] OR “Incidence Studies” [tiab]
OR “Incidence Study” [tiab] OR “Concurrent Studies” [tiab] OR “Concurrent Study” [tiab] OR “Follow Up” [tiab] OR random*[tiab] OR
trial* [tiab] OR (“case”[tw] AND “control”[tw]) OR “comparative study”[mesh])
#4 (#1 AND #2 AND #3)
#5 animals [mesh] NOT (humans [mesh] AND animals [mesh])
#6 #4 not #5
confounders. For trials with multiple intervention groups or
varying doses of iron, we extracted data for eligible comparison
groups. For cluster randomised trials, we extracted estimates
adjusted for the cluster design. We incorporated data such that
each participant was included in an analysis only once to avoid
unit of analysis error. We assessed each trial’s methodological
quality by using four criteria—namely, randomisation technique,
concealment of allocation, blinding, and loss to follow-up. We
categorised each criterion as adequate, inadequate, or unclear.
We labelled a trial as high quality if it was rated as adequate for
randomisation and allocation concealment plus either blinding
or loss to follow-up under 20%.We assessed themethodological
quality of cohort studies by comparing crude and adjusted
estimates, controlling for the study confounders. Eligible foreign
language papers were translated into English; however, 11
foreign language papers could not be translated and were not
included (see table supplement for referencesw1-11). We actively
contacted study authors to seek clarifications and request missing
or additional data or reanalysis, if needed. Discrepancies
between the reviewers were resolved through discussion, by
contacting the authors, or by consultation with a third reviewer
(WWF or ME).
Statistical analysis
Weused fixed effects (Mantel-Haenszel method16 17) and random
effects (DerSimonian and Laird method18) models to calculate
summary estimates for the overall effect of iron, with or without
folic acid, followed by separate meta-analyses for the effects
of iron alone and iron with folic acid. We present summary
effects as relative risks for binary outcomes and as mean
differences for continuous outcomes, with their respective 95%
confidence intervals. To study the effect of methodological
quality of trials, we did sensitivity analyses using data from
high quality trials only. We did meta-analyses for outcomes
with data for at least five trials or comparison groups.
We assessed presence of between study heterogeneity by using
the Q statistic with its P value and I2 statistics.19 20 The I2 statistic
is used to quantify the proportion of total variation in the effect
estimation that is due to between study variation. If the Q
statistic P value was below 0.10 and I2 exceeded 50%, we
considered heterogeneity to be substantial and presented a
random effects model. We explored sources of heterogeneity
through subgroup and meta-regression analyses,21 using the
pre-specified subgroups based on trials’ characteristics: country
category (low or middle income versus high income),22 malaria
endemicity (endemic versus non-endemic), initial mean
haemoglobin concentration (anaemic (<110 g/L) versus
non-anaemic (≥110 g/L)), and gestational age at start of
treatment (early as ≤21 weeks versus late as >22 weeks of
gestation). As malaria endemicity was not available for most
included studies, we used the malaria atlas project database to
characterise endemicity of the study area within a country,23
assuming that the endemicity had not changed. Study areas with
stable malaria transmission were labelled as endemic, whereas
those with unstable transmission or that were risk free were
categorised as non-endemic. We further investigated sources
of heterogeneity by doing meta-regression analysis and used
the residual I2 to estimate residual heterogeneity after adjusting
for the characteristic of interest. We assessed publication bias
by visual inspection of funnel plots for asymmetry and through
Begg’s rank correlation and Egger’s linear regression tests.24 25
We did subgroup analysis and assessments of publication bias
for outcomes with 10 or more trials or comparison groups.
We examined the iron dose-response relation with risk of
maternal anaemia, low birth weight, and preterm birth by using
methods proposed by Greenland et al and Orsini et al, which
take into account the correlation between log-relative risk
estimates across the exposure categories.26 27 To evaluate a
potential non-linear dose-response relation, we fitted fixed
effects restricted cubic spline regressionmodels using four knots
at the fifth, 35th, 65th, and 95th centiles of the exposure data
and assessed significance of spline variables through hypothesis
testing.28 For the iron dose-response relation with birth weight,
we used a mixed effects meta-regression model to estimate the
mean change in birth weight per unit change in iron dose.29 We
evaluated non-linearity by using the regression model described
above. We also assessed the association with duration of iron
use in the above models by adding study specific durations. We
assessed the exposure-response relations of mean haemoglobin
concentration in the third trimester or at delivery with birth
weight and risk of low birth weight and preterm birth by using
these statistical methods. We did sensitivity analysis, subgroup
analysis, and assessments of publication bias and
exposure-response relation only for the overall analysis of iron
use, with or without folic acid.
For the meta-analysis of cohort studies, we used odds ratios or
mean differences to calculate summary measures. We did a
separate meta-analysis for cohort studies to study the association
of baseline haemoglobin with the outcomes and to assess
whether the findings from cohorts and trials were consistent.
We did sensitivity analysis by analysing study specific crude
odds ratios and adjusted odds ratios separately and comparing
the summary estimates to establish the effect of adjustment for
confounders. We assessed presence of between study
heterogeneity by using the methods described above. We used
the following pre-specified study characteristics for subgroup
analysis: period of gestation of anaemia assessment (first and
second trimester (<27 weeks of gestation) versus third trimester
(≥27 weeks)), country category, and malaria endemicity. We
used funnel plots and Harbord’s test to assess publication bias.30
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We did not use Egger’s test owing to the statistical problem of
standard error of log odds ratio being mathematically linked to
the size of log odds ratio, even in the absence of small study
effects. For the exposure-response analysis of haemoglobin
concentration on birth weight, low birth weight, and preterm
birth, mean haemoglobin concentrations for the anaemic and
non-anaemic groups were not available for all cohort studies.
To evaluate this relation, we selected a country from each high,
middle, and low income countries category and used their mean
haemoglobin concentrations for studies with missing values.
We selected studies in Hong Kong, China, and HIV negative
women in Tanzania for high income, middle income, and low
income categories. We used the statistical methods described
above to evaluate the exposure-response relations.
We used Stata (version 10.1), SAS (version 9.2), and RevMan
(version 5.1) for the analyses. Statistical significance was
defined at the 0.05 level.
Results
Literature search
Figure 1⇓ shows results from the literature search and study
selection process. We identified a total of 13 668 potentially
eligible citations, of which 5882 were from PubMed and 7786
from Embase. Screening of 10 821 titles and abstracts after
removing duplicates identified 1048 citations for full text review.
An additional 12 references were identified from reference lists
of previously published reviews. Detailed review of identified
full text papers yielded 152 reports of 120 eligible studies,
including 62 randomised trials and 58 cohort studies. Of 120
studies, we further excluded 28 studies as data were either
missing or presented in a format that precluded inclusion (see
table supplement for referencesw12-39).
Study characteristics
Supplementary tables 1 and 2 show the characteristics of
included trials and cohort studies. Briefly, 17 793 pregnant
women were included in 48 randomised trials, of which 27 were
conducted in high income countries (4861 women)31-57 and 21
in low or middle income countries (12 932 women).58-78 Thirty
four trials compared the effect of daily iron use with no iron or
placebo, four trials compared iron with folic acid versus folic
acid alone, 14 trials included a comparison of iron with folic
acid versus placebo or no treatment, and 10 compared iron with
a micronutrient or several micronutrients versus the same set
of micronutrients except iron. Two trials evaluated the effect
of iron fortification compared with no fortification.47 61 Eighteen
trials had adequate randomisation, allocation concealment, and
blinding or loss to follow-up under 20% (supplementary table
1).31 32 36 38 41 42 45 47 52-54 58 63 66 70 71 73 79 Only two trials randomised
villages or sectors (clusters).58 74 The dose of iron in included
trials ranged from 10 mg to 240 mg daily; one trial used a daily
dose of 900 mg.37 Duration of supplementation varied from
seven to eight weeks up to 30 weeks during pregnancy. One
trial also randomised participants to malaria prophylaxis and
another randomised them to anti-helminthic drugs, along with
the intervention and control treatment.63 70
We included 44 cohort studies including 1 851 682 women. Of
these, 22 studies were from high income countries (650 126
women)80-101 and 22 were from low or middle income countries
(1 201 556 women).102-123 Anaemia was defined differently in
included studies, with definitions ranging from haemoglobin
<100 g/L to haemoglobin <115 g/L. Studies assessed anaemia
at varying times during pregnancy (17 measured haemoglobin
values in the first or second trimester and nine in the third
trimester). Five studies measured concentrations in all three
trimesters of pregnancy, in which case we included first trimester
values in the analysis. Eight studies used values measured at
the first antenatal visit, whereas in 10 studies the time of
assessment of anaemia was not specified (supplementary table
2).
Evidence from randomised trials
We firstly present findings for the overall effect of iron, with
or without folic acid, followed by the effect of iron only and
iron with folic acid.
Findings for overall effect of iron, with or without
folic acid, on haematological outcomes
Table 1⇓ summarises the overall effect of iron on haematological
outcomes. We included 36 trials measuring haemoglobin
concentration in the third trimester or at delivery and showed a
significantly higher mean haemoglobin concentration in the
iron, with or without folic acid, group (mean difference 4.59
g/L, 95% confidence interval 3.72 to 5.46; 36 trials; fig 2⇓).We
found no heterogeneity associated with this analysis (I2=0%;
P>0.05). The funnel plot did not suggest evidence of publication
bias (fig 3⇓), whereas Egger and Begg tests were significant
(both P<0.05). We found the effect of iron on the postpartum
haemoglobin concentration to be significant, whereas that on
the second trimester haemoglobin concentration was
non-significant (supplementary figures 1 and 2). The effect of
intervention on maternal anaemia was assessed in 21 trials. Use
of iron, with or without folic acid, led to 50% reduction in risk
of anaemia in the third trimester or at delivery (relative risk
0.50, 0.42 to 0.59; 19 trials; table 1⇓, supplementary figure 3).
Heterogeneity was significant, and results should be interpreted
with caution (P<0.001; I2=83%). A visual inspection of the
forest plot indicated that heterogeneity could be due to variation
in the degree of difference in effect rather than the direction.
The funnel plot and Begg and Egger tests (both P<0.05)
suggested publication bias (supplementary figure 4). Effects on
the second trimester or postpartum concentrations could not be
evaluated owing to the small number of trials (less than five).
Because haemoglobin concentration is an important indicator
of maternal health, we did subgroup analysis to study the effects
in various pre-specified subgroups. Mean haemoglobin
concentration in the third trimester or at delivery was
significantly higher in the low or middle income country
category than in the high income category (test P=0.003) and
for initial mean haemoglobin concentrations <110 g/L versus
≥110 g/L (test P=0.005) (table 2⇓). We identified no significant
difference for malaria endemicity and time of start of iron use
in subgroups (both test P>0.05). Meta-regression analyses for
maternal anaemia showed that the effects were significantly
larger in the high income country category (test P=0.009), with
initial mean haemoglobin concentration ≥110 g/L (test P=0.008),
and in malaria non-endemic regions (test P=0.003). Adjusting
for these covariates independently in meta-regression did not
explain heterogeneity substantially (table 3⇓).
Use of iron, with or without folic acid, also provided significant
improvements in iron indicators in the third trimester or at
delivery; analysis showed significant reductions in the risk of
iron deficiency (relative risk 0.59, 0.44 to 0.79; I2=79%; eight
trials) and iron deficiency anaemia (0.40, 0.26 to 0.60; I2=33%;
six trials) (table 1⇓; supplementary figures 5 and 6). Sources of
heterogeneity for iron deficiency could not be evaluated owing
to the small number of available trials.
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Findings for overall effect of iron, with or without
folic acid, on birth outcomes
Analysis showed a significantly higher mean birth weight in
the iron group comparedwith the control group (mean difference
41.2 (1.2 to 81.2) g; I2=99%; 19 trials; table 1⇓, supplementary
figure 7). Analysis of the high quality trials alone also indicated
a significant effect (mean difference 68.7 (37.7 to 99.7) g;
I2=97%; 12 trials). Heterogeneity was high, but subgroup
analysis and meta-regression showed that birth weights were
not significantly different in subgroups (test P>0.05). Iron use
led to a reduction of 19% in risk of low birth weight (relative
risk 0.81, 0.71 to 0.93; I2=1%; 13 trials; table 1⇓, fig 4⇓). The
analysis of the high quality trials alone found similar results
(table 1⇓). The funnel plot and Begg and Egger tests for low
birth weight and for birth weight suggested no evidence of
publication bias (all P>0.05); however, the funnel plot for birth
weight indicated some asymmetry.
Use of iron did not have a significant effect on preterm birth,
duration of gestation, small for gestational age births, and birth
length (P>0.05) (table 1⇓; supplementary figures 8-11).
Sensitivity analyses found similar effects among the high quality
trials. The funnel plot and Egger and Begg tests (both P>0.05)
for preterm birth did not suggest the presence of publication
bias. A small number of trials reported effects on stillbirths
(n=3), perinatal mortality (n=4), neonatal mortality (n=3), and
maternal morbidity outcomes such as gestational diabetes (n=1),
infection during pregnancy (n=2), puerperal sepsis (n=2), and
malaria indicators (n=2), precluding further analyses for these
outcomes.
Exposure-response relation of iron dose with
haematological and birth outcomes
We noted a significant non-linear, inverse relation between dose
of iron and risk of maternal anaemia in the third trimester or at
delivery (non-linear test P<0.001; 18 trials; table 4⇓;
supplementary figure 12). The relation did not change when we
excluded the trial that used 900 mg of iron daily37 (non-linear
test P<0.001; 17 trials; table 4⇓). Because the iron dose
recommended is either 60 mg or lower,124 125 we restricted
analysis to trials providing up to 66 mg iron/day to see if giving
60 mg daily has any benefit over lower doses. For a 10 mg
increase in iron dose per day, the relative risk of anaemia was
0.88 (0.84 to 0.92; P for linear trend<0.001; 11 trials; table 4⇓;
supplementary figure 13). We used duration data from trials to
evaluate the association of duration of use with anaemia;
duration of use, adjusted for dose of iron, was not associated
with anaemia (P>0.05).
Analysis of the exposure-response relation between iron dose
and birth weight found an increase of 15.1 (6.0 to 24.2) g in
birth weight for every 10 mg increase in daily iron dose
(P=0.005; 18 trials; table 4⇓). Similarly, risk of low birth weight
decreased by 3% for every 10 mg increase in daily iron dose
(relative risk 0.97, 0.95 to 0.98; P for linear trend<0.001; 13
trials; table 4⇓). We found no evidence of a non-linear
association with either birth weight or low birth weight (both
P>0.05). When we restricted analyses to trials using up to 66
mg/day iron, findings for low birth weight did not change (table
4⇓; supplementary figure 14); however, we found evidence of
non-linearity for birth weight (P<0.001; 14 trials; supplementary
figure 15). Duration of iron use was not significantly associated
with either outcome, after adjustment for dose. Iron dose was
not associated with risk of preterm birth (relative risk 0.99, 0.95
to 1.04; P for linear trend=0.67; 12 trials; table 4⇓).
Exposure-response relation of haemoglobin
concentration with birth outcomes
A unit increase in mean haemoglobin concentration in the third
trimester or at delivery linearly increased birth weight by 14.0
(6.8 to 21.8) g (P=0.002; 16 trials; table 5⇓). We found no
evidence of a non-linear association (P>0.05; supplementary
figure 16). However, the effect on risk of low birth weight was
non-significant (relative risk 0.96, 0.84 to 1.09; P for linear
trend=0.21; 11 trials; table 5⇓, supplementary figure 17).
Similarly, the effect on risk of preterm birth was also
non-significant (relative risk 0.99, 0.94 to 1.04; P for linear
trend=0.70; eight trials; table 5⇓, supplementary figure 18).
Findings for effect of iron only versus no
iron/placebo on haematological and birth
outcomes
Use of iron was associated with significantly increased mean
haemoglobin concentration in the third trimester or at delivery
(mean difference 4.50 (3.62 to 5.39) g/L; I2=0%; 31 trials;
supplementary figure 19) and in the postpartum period (7.01
(0.36 to 13.66) g/L; I2=0%; eight trials; supplementary figure
20) compared with no iron or placebo. Similar to the overall
analysis, we found significant reductions in the risk of anaemia
(relative risk 0.56, 0.48 to 0.65; I2=75%; 17 trials), iron
deficiency (0.59, 0.44 to 0.79; I2=79%; eight trials), and iron
deficiency anaemia (0.37, 0.23 to 0.60; I2=47%; five trials)
(supplementary figures 21-23). Heterogeneity was significant,
and findings should be interpreted with caution. However, visual
inspection of the forest plots indicated that heterogeneity seemed
to be due to the variation in effects sizes, rather than the
direction of the effect. Use of iron was associated with a
significant increase in birth weight (mean difference 40.8 (0.97
to 80.6) g; I2=99%; 16 trials) and reduction in risk of low birth
weight (relative risk 0.81, 0.71 to 0.91; I2=9%; 10 trials). Effects
on duration of gestation (mean difference 0.11 (−0.35 to 0.57)
weeks; nine trials), preterm birth (relative risk 0.92, 0.80 to
1.07; 10 trials), small for gestational age births (relative risk
0.84, 0.66 to 1.07; six trials), and birth length (mean difference
−0.93 (−4.76 to 2.90) cm; seven trials) were not significant
(supplementary figures 24-29)
Findings for effect of iron with folic acid versus
no iron and folic acid/placebo on haematological
and birth outcomes
Iron with folic acid was associated with a significant increase
in mean haemoglobin concentration (mean difference 10.41
(5.36 to 15.46) g/L; I2=0%; nine trials) and reduction in risk of
anaemia in the third trimester or at delivery (relative risk 0.44,
0.37 to 0.53; I2=44%; five trials) (supplementary figures 30 and
31). Effects on other haematological and pregnancy outcomes
could not be evaluated owing to the small number of available
trials (less than five).
Evidence from cohort studies
Association between anaemia and birth outcomes
Table 6⇓ summarises the association between prenatal anaemia,
irrespective of the time of assessment, and birth outcomes.
Prenatal anaemia significantly increased the risk of low birth
weight compared with no anaemia (crude odds ratio 1.25, 1.08
to 1.45; I2=90%; 25 studies); however, the association was
non-significant when we pooled adjusted estimates extracted
from the included studies (adjusted odds ratio 1.13, 0.94 to 1.35;
I2=86%; nine studies) (supplementary figures 32 and 33). We
noted a significantly higher risk of preterm birth in the anaemic
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group (crude odds ratio 1.28, 1.12 to 1.47; I2=89%; 26 studies).
This association remained significant when we pooled adjusted
estimates (adjusted odds ratio 1.28, 1.11 to 1.48; I2=83%; 13
studies) (supplementary figures 34 and 35). We found a
significantly higher risk of stillbirth in the anaemic group (crude
odds ratio 1.19, 1.09 to 1.29; I2=24%; 12 studies; supplementary
figure 36); however, adjusted estimates could not be pooled
because only two studies presented them. Anaemia was
marginally associated with the duration of gestation (P=0.05)
but not with birth weight; associations with small for gestational
age births and perinatal mortality were not significant (P>0.05)
(supplementary figures 37-41). Associations with birth length
and neonatal mortality could not be evaluated owing to paucity
of data.
We found significant heterogeneity in the preterm birth and low
birth weight analyses. Subgroup analysis found a significantly
higher risk of preterm birth with first or second trimester
anaemia (adjusted odds ratio 1.21, 1.13 to 1.30; I2=0%; seven
studies) but not with third trimester anaemia (adjusted odds
ratio 1.20, 0.80 to 1.79; I2=90%; six studies) (test P=0.71)
(supplementary table 3). We found no significant difference for
subgroups of country category (high (adjusted odds ratio 1.26,
1.02 to 1.57; I2=87%; nine studies) versus low or middle income
countries (adjusted odds ratio 1.30, 1.05 to 1.61; I2=77%; five
studies) (test P=0.83) (supplementary table 3). We could not do
subgroup analysis for malaria endemicity owing to the small
number of studies in one of the subgroups. Supplementary table
4 presents findings for the low birth weight subgroup analysis,
which showed significantly higher risk with first or second
trimester anaemia (adjusted odds ratio 1.29, 1.09 to 1.53;
I2=82%; six studies) and no significant associations in subgroups
of high income countries (adjusted odds ratio 1.21, 0.95 to 1.53;
I2=90%; six studies) or malaria non-endemic countries (adjusted
odds ratio 1.13, 0.94 to 1.35; I2=86%; nine studies); however,
we could not calculate P values for subgroup differences owing
to the small number of studies in one of the subgroups. Funnel
plots and Harbord tests for low birth weight and preterm birth
(both P>0.05) did not suggest any evidence of publication bias.
Exposure- response relation of haemoglobin
concentration with birth outcomes
Analysis of the cohort studies showed non-significance of the
exposure-response relation between mean haemoglobin
concentration and birth weight (mean difference 3.2 (−17.9 to
24.3) g; P=0.77; nine studies; supplementary table 5). More
studies assessed the association with low birth weight, and the
association was significant although the magnitude was small
(relative risk 0.99, 0.98 to 0.99; P for linear trend<0.001; 25
studies; supplementary table 5). We also found the
exposure-response relation of mean haemoglobin concentration
in the first or second trimester with risk of preterm birth to be
significant (relative risk 0.98, 0.98 to 0.99; P for linear
trend<0.001; 12 studies; supplementary table 5).
Discussion
In meta-analyses of randomised trials of prenatal iron use, we
found evidence of significant reductions in maternal anaemia,
iron deficiency, iron deficiency anaemia, and risk of low birth
weight. Dose-response analysis showed a linear decrease in
maternal anaemia with higher doses of iron, up to 66 mg/day.
Higher doses of iron were associated with a linear increase in
birth weight and decrease in risk of low birth weight. With iron
up to 66 mg/day, we found a non-linear association with birth
weight but a linear reduction in risk of low birth weight.
Furthermore, higher mean haemoglobin concentration in the
prenatal period linearly increased birth weight with a
dose-response relation. We did not find any evidence of
reduction in risk of preterm birth as a result of iron use; however,
meta-analysis of cohort studies indicated a higher risk of preterm
birth with first or second trimester anaemia and with lower mean
haemoglobin concentration.
Strengths of meta-analysis in relation to other
meta-analyses
This meta-analysis is a comprehensive evaluation of the
evidence, incorporating randomised trials and cohort studies,
with examination of associations with haematological,
morbidity, and birth outcomes in one report. To the best of our
knowledge, this is the first meta-analysis to examine the
exposure-response relation of dose of iron, duration of use, and
haemoglobin concentration on birth weight and risk of low birth
weight and preterm birth. We made various comparisons
evaluating the overall effect of iron, iron only, and iron with
folic acid. We made an effort to extract all available data from
trials, especially those with multiple comparison groups. In
addition, we evaluated effects in various predefined subgroups
and did meta-regression to evaluate sources of heterogeneity.
We also did sensitivity analysis to assess the effect of the
methodological quality of trials on effect estimates.
Results in relation to other meta-analyses
Our findings of significant improvement in maternal
haematological outcomes as a result of iron use corroborate
those of previous reviews.12 14 126 127 We noted a greater effect
on haemoglobin concentration in low ormiddle income countries
and with lower initial mean haemoglobin concentration (<110
g/L). We showed a positive, linear dose-response relation
between iron dose up to 66 mg daily and risk of maternal
anaemia, indicating a benefit of giving higher rather than lower
doses over this range. These findings are biologically plausible,
as several mechanisms regulating intestinal iron absorption have
been identified.77 128 129 Human studies and animal models have
shown that depleted body iron stores enhance absorptive
capacity in the duodenum, which is increased several-fold in
the presence of iron deficiency. Another important regulator is
bone marrow erythropoiesis, which adjusts intestinal absorption
in response to the erythropoietic demands. Review of
epidemiological studies shows that women in low or middle
income countries generally enter pregnancy with more limited
iron stores and lower haemoglobin concentrations than do those
in high income countries. An increasing demand for iron in
these womenmay thus enhance intestinal absorption to a greater
extent, resulting in a greater haematological response. Improved
haematological status during pregnancy may also reduce the
mortality risk in women with antepartum or postpartum
haemorrhage and lead to improved iron status in the postpartum
period.9 11
We found a significant reduction in the risk of low birth weight
as a result of iron use, which is similar to the finding of Imdad
et al.130 This, however, is in contrast to that of the Cochrane
review,12 which did not find evidence of a decreased risk. We
present below a brief description of the methodological
differences between the various meta-analyses. The Cochrane
review included 45 randomised and quasi-randomised trials
identified up to March 2009 and found no significant effect on
birth weight, low birth weight, preterm birth, and small for
gestational age births.12 We, in this meta-analysis, included
larger number of randomised trials with searches updated to 31
May 2012. We excluded quasi-randomised trials, as these have
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a high risk of bias owing to the inadequate method of random
sequence generation or allocation concealment. The differences
in the eligibility criteria for selecting studies between the two
reviews and the dates of literature search led to a different set
of trials being analysed in the two reviews. Imdad et al evaluated
a smaller set of outcomes and identified 30 randomised and
quasi-randomised trials up to June 2011.130 The analyses were
associated with significant heterogeneity, but the sources of
heterogeneity were not examined using study characteristics.
Yakoob et al and Sloan et al included randomised and
quasi-randomised trials evaluating effects on haematological
outcomes only.126 127 None of the earlier reviews did
meta-regression to evaluate sources of heterogeneity or an
assessment of exposure-response relations, which were
objectives of our meta-analysis.
The dose-response analysis showed a linear increase in birth
weight with higher iron doses. More importantly, higher mean
haemoglobin concentration linearly increased birth weight.
These results indicate that for every 10 g/L increase in mean
haemoglobin concentration in the third trimester or at delivery,
the birth weight would increase by 143 (95% confidence interval
68 to 218) g. The dose of iron recommended by WHO is 60
mg/day, whereas the Institute of Medicine has set the tolerable
upper intake level as 45 mg/day owing to the gastrointestinal
side effects with higher doses.124 125 Trials comparing various
doses of iron have been done and indicate a larger improvement
in iron status with higher doses, but no difference in anaemia
and other clinical outcomes was noted.131 132 We also showed a
reduction in risk of low birth weight with higher iron doses and
identified a similar relation with iron dose up to 66 mg/day. An
increase in birth weight of the magnitude specified above could
prove critical for the survival of neonates born with birth weights
in the lower range.133Recent literature also provides insight into
the biological mechanisms that could potentially explain the
effects on birth weight. A potential role of the placenta in the
regulation of iron transfer and the transport proteins involved
has been identified.78 134 135 Animal models also indicate a role
of fetal liver iron stores in regulating iron absorption through
the placenta.135 136 In contrast to the significant effect on birth
weight from trials, this meta-analysis of cohort studies did not
indicate a significant increase in birth weight with increasing
haemoglobin concentration. Several reasons for this observation
are possible. Firstly, as the data used in this analysis were
observational in nature, confounding of the association could
have occurred. Secondly, as the mean haemoglobin
concentrations for most studies were missing, we assumed that
countries within the same category would have similar mean
haemoglobin concentrations. Under that assumption, we used
similar values for all countries in low, middle, or high income
categories, which may not have been completely accurate.
Our analysis of cohort studies showed a significantly increased
risk of preterm birth with first or second trimester anaemia.
These results are in agreement with previous reviews of
observational studies.10 11 Xiong et al included 10 observational
studies published up to 1999 in their review.10 Both cohort and
case-control studies were included in this review. The Global
Burden of Disease Comparative Risk Assessment analysis of
iron deficiency anaemia included 10 studies examining
association with perinatal mortality outcome.9 This review
included cross sectional studies examining the association of
haemoglobin measured at delivery with pregnancy outcomes,
together with other observational designs. Cross sectional and
case-control studies do not allow evaluation of the temporal
association between the exposure and outcome, and they have
high risk of bias. These were, therefore, excluded from our
meta-analysis. We also did sensitivity and subgroup analyses
and explored exposure-response relations between haemoglobin
concentration and birth outcomes, which were not included in
earlier reviews of observational studies. Although we found a
significant risk of preterm birth in our meta-analysis of cohort
studies, the meta-analysis of trials indicated a non-significant
effect of iron use on preterm birth risk. It is plausible that causes
of anaemia other than iron deficiency are implicated in the
pathway; a few have been identified.120 Existence of chronic
hypoxia may induce a stress response, resulting in production
of corticotrophin releasing hormone, elevated concentrations
of which have been identified as a major risk factor of preterm
birth. Additionally, the risk of preterm birth may increase owing
to oxidative damage to erythrocytes and the fetoplacental unit.
Lastly, it may increase the risk of infections, stimulating
production of corticotrophin releasing hormone and increasing
the risk of preterm birth.
A potential concern exists regarding an increased risk of adverse
maternal and birth outcomes associated with high haemoglobin
concentrations. Several studies have found increased risks of
low birth weight, preterm birth, and small for gestational age
birth with high maternal haemoglobin concentrations.94 97 119 137
The adverse birth outcomes may be comparable to those of
anaemia, but the causes may be different.121 137 This, however,
warrants further investigation and was not a part of our review.
The interaction between iron supplementation and susceptibility
to infections, including malaria, also remains a concern. Studies
of iron supplementation of children inmalaria endemic countries
suggest that iron supplementation increases the risk of morbidity
andmortality among children138 139; however, studies of antenatal
iron use have shown conflicting results for malaria
outcomes.68 140 141 We could not evaluate these outcomes in this
review owing to the paucity of data.
Limitations of meta-analysis
Our review has several limitations. Firstly, we could not evaluate
associations with several outcomes owing to the paucity of data.
These include stillbirths and neonatal and perinatal mortality
in iron use meta-analyses and birth length and neonatal mortality
in the cohort studies analysis. Secondly, significant
heterogeneity existed for several outcomes that could not be
explained substantially by our pre-specified subgroups. This
limits our understanding of the association in various settings
and restricts the generalisability of our findings. Thirdly, a small
number of trials had evaluated the effect of iron fortification in
pregnant women, so a separate meta-analysis for fortification
trials could not be done. Fourthly, although we used adjusted
estimates from cohort studies, these results still could have been
biased owing to residual confounding, in either direction,
depending on the nature of the residual confounding. Finally,
as explained earlier, for the exposure-response analysis of cohort
studies, we assumed mean haemoglobin concentrations for
studies with missing values, which may have introduced bias
towards the null due to random measurement error.
Conclusions: implications for practice and
future research
Our findings suggest that use of iron in women during pregnancy
may be used as a preventive strategy to improve maternal
haematological status and birth weight. Prenatal anaemia and
iron deficiency have been identified as one of the preventable
risk factors for disease with a substantial disease burden.142 This
calls for a rigorous evaluation of the effectiveness of existing
antenatal care programmes in high burden countries to identify
gaps in policy and programme implementation. Targeted
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interventions to strengthen the infrastructure of antenatal care
should be used. Future research to explore feasible strategies
of iron delivery in a country setting and evaluation of the
effectiveness of other strategies, such as fortification and dietary
diversification, should be done.
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What is already known on this topic
Synthesis of evidence from observational studies indicates an association between prenatal anaemia and risk of preterm birth, but
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Evidence from randomised trials on the effect of prenatal iron use on adverse birth outcomes is also inconclusive
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This comprehensive meta-analysis of randomised trials suggests that prenatal iron use is associated with a significant increase in birth
weight and reduction in risk of low birth weight
A dose-response relation of higher iron dose with increasing birth weight and decreasing risk of low birth weight exists
An exposure-response relation also exists between increasing mean haemoglobin concentration in the prenatal period and higher birth
weight
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Tables
Table 1| Summary of effects of iron use on haematological and pregnancy outcomes
High quality trialsAll trialsHaematological
outcomes (in third
I2 (%)
Test for
heterogeneity
(P value)
Significance
of effect (P
value)
WMD or RR (95%
CI)
No of
trialsI2 (%)
Test for
heterogeneity
(P value)
Significance
of effect (P
value)
WMD or RR (95%
CI)
No of
trials
trimester or at
delivery)
00.95<0.0014.20 (3.17 to 5.22)1500.98<0.0014.59 (3.72 to 5.46)36Haemoglobin (g/L)
72<0.001<0.0010.66 (0.57 to 0.76)883<0.001<0.0010.50 (0.42 to 0.59)19Anaemia
790.001<0.0010.70 (0.55 to 0.91)579<0.001<0.0010.59 (0.44 to 0.79)8Iron deficiency
————4330.18<0.0010.40 (0.26 to 0.60)6Iron deficiency
anaemia
Pregnancy outcomes
97<0.001<0.00168.67 (37.67 to
99.68)
1299<0.001<0.00141.21 (1.20 to
81.23)
19Birth weight (g)
370.150.0030.82 (0.72 to 0.94)710.440.0010.81 (0.71 to 0.93)13Low birth weight
01.000.630.12 (-0.36 to 0.60
)
601.000.640.11 (-0.35 to 0.57)10Gestational age
(weeks)
00.670.120.84 (0.68 to 1.05)900.680.090.84 (0.68 to 1.03)12Preterm birth
700.0050.260.84 (0.62 to 1.14)6590.020.170.85 (0.67 to 1.08)8Small for gestational
age birth
00.410.58−1.15 (−5.15 to
2.84)
600.760.58−1.08 (−4.97 to
2.80)
8Birth length (cm)
RR=relative risk; WMD=weighted mean difference.
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Table 2| Subgroup analysis for effect of iron use on haemoglobin concentration in third trimester or at delivery (g/L)
Test for interaction (P value)Significance of effect (P value)Mean difference (95% CI)No of trialsCharacteristic
0.003Country:
<0.0018.34 (5.69 to 11.00)14Low or middle income
<0.0014.13 (3.21 to 5.06)22High income
0.087Malaria endemicity:
<0.0018.16 (3.98 to 12.34)7Endemic
<0.0014.43 (3.53 to 5.32)29Non-endemic
0.005Baseline anaemia:
<0.00110.17 (6.14 to 14.19)7Anaemic
<0.0014.29 (3.39 to 5.19)26Non-anaemic
0.086Start of iron use:
<0.0014.48 (3.60 to 5.36)32Early (≤21 weeks’ gestation)
<0.0019.73 (3.80 to 15.66)4Late (>22 weeks’ gestation)
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Table 3| Subgroup analysis and meta-regression for effect of iron use on maternal anaemia in third trimester or at delivery
Univariate meta-regression
Relative risk (95% CI)No of trialsCharacteristic
Reduction in I2 after
adjustment for covariate
(%)
Residual I2 after
adjustment for covariate
(%)
P value for test for
heterogeneity by covariate
1820.009Country:
0.58 (0.50 to 0.67)8Low or middle income
0.23 (0.12 to 0.45)11High income
5790.003Malaria endemicity:
0.61 (0.53 to 0.71)6Endemic
0.30 (0.19 to 0.46)13Non-endemic
10740.008Baseline anaemia:
0.60 (0.51 to 0.71)5Anaemic
0.32 (0.21 to 0.50)12Non-anaemic
0840.60Start of iron use:
0.50 (0.39 to 0.65)13Early (≤21 weeks of gestation)
0.45 (0.33 to 0.61)6Late (>22 weeks of gestation)
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Table 4| Summary of exposure-response relations with haematological and birth outcomes (trials)
P valueWMD or RR (95% CI)No of trialsExposure: increase in iron dose (10 mg/day)
Maternal anaemia
<0.0010.99 (0.990 to 0.995)18All trials
<0.0010.93 (0.91 to 0.94)17All trials (excluding trial with iron dose 900 mg/day)
<0.0010.88 (0.84 to 0.92)11Trials with iron dose up to 66 mg/day
Low birth weight
<0.0010.97 (0.95 to 0.98)13All trials
<0.0010.96 (0.95 to 0.98)11Trials with iron dose up to 66 mg/day
Birth weight
0.00515.10 (6.00 to 24.20)18All trials
0.00416.70 (7.29 to 26.11)14Trials with iron dose up to 66 mg/day
Preterm birth
0.670.99 (0.95 to 1.04)12All trials
0.500.99 (0.95 to 1.03)11Trials with iron dose up to 66 mg/day
RR=relative risk; WMD=weighted mean difference.
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Table 5| Summary of exposure-response relations of haemoglobin difference* (1 g/L) in prenatal period with birth outcomes (trials)
P valueWMD or RR (95% CI)No of trialsOutcomes
0.210.96 (0.84 to 1.09)11Low birth weight
0.00214.00 (6.80 to 21.80)16Birth weight
0.700.99 (0.94 to 1.04)8Preterm birth
RR=relative risk; WMD=weighted mean difference.
*Difference in mean haemoglobin concentration between intervention and control groups in included studies.
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Table 6| Summary estimates of anaemia, irrespective of time of anaemia assessment, on pregnancy outcomes (cohort studies)
Adjusted estimatesUnadjusted estimates
Outcome I2 (%)
Test for
heterogeneity
(P value)
Significance
of effect (P
value)
Adjusted OR or
MD (95% CI)
No of
studiesI2 (%)
Test for
heterogeneity
(P value)
Significance
of effect (P
value)
Crude OR or MD*
(95% CI)
No of
studies
–———070<0.0010.33−20.15 (−60.91 to
20.61)
9Birth weight
86<0.001<0.0011.13 (0.95 to
1.35)
990<0.0010.0031.25 (1.08 to 1.45)25Low birth weight
————081<0.0010.05−0.37 (−0.74 to
−0.00)
6Gestational age
83<0.0010.0011.28 (1.11 to
1.48)
1389<0.001<0.0011.28 (1.12 to 1.47)26Preterm birth
88<0.0010.431.08 (0.90 to
1.29)
992<0.0010.771.04 (0.80 to 1.35)13Small for
gestational age
————2240.21<0.0011.19 (1.09 to 1.29)12Stillbirth
————2670.0030.861.03 (0.77 to 1.37)8Perinatal
mortality
MD=mean difference; OR=odds ratio.
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Figures
Fig 1 Flow diagram of identification process for eligible studies
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Fig 2 Forest plot for effect of iron use on mean haemoglobin concentration (g/L) in third trimester or at delivery. I−V=inverse
variance method; D+L=DerSimonian and Laird method
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Fig 3 Funnel plot (with pseudo 95% confidence limits) for effect of iron use on mean haemoglobin concentration (g/L) in
third trimester or at delivery
Fig 4 Forest plot for effect of iron use on low birth weight. I−V=inverse variance method; D+L=DerSimonian and Laird
method
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